Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Citizen Petition Urges FDA To Control Diagnostic Tests

By LabMedica International staff writers
Posted on 23 Dec 2008
A citizen petition was filed with the US Food and Drug Administration (FDA; Rockville, MD, USA) urging the agency to take on greater control of diagnostic tests that are intended to guide therapeutic decisions and to regulate all laboratory-developed tests (LDT).

The biopharmaceutic firm Genetech (South San Francisco, CA, USA) which filed the citizen petition, is involved in an issue that disturbs many molecular diagnostic manufacturers who are awaiting the FDA's final guidance on in vitro diagnostic multivariate index assays (IVDMIAs). More...
A draft guidance on IVDMIAs was issued in September 2006. The FDA said then that such tests, normally overseen by Clinical Laboratory Improvement Amendments (CLIA) regulations, must instead be cleared by the agency because of their complexity. CLIA regulates all laboratory testing (except research) performed on humans in the United States for The Centers for Medicare & Medicaid Services (CMS).

According to a draft document, which consisting of nonbinding recommendations by the FDA (July 26, 2007), IVDMIAs raise significant issues of safety and effectiveness. These types of tests are developed based on observed correlations between multivariate data and clinical outcome, such that the clinical validity of the claims is not transparent to patients, laboratory personnel, and clinicians who order the tests. They do not fall within the scope of LDTs over which FDA has generally exercised enforcement discretion.

In general, an IVDMIA might use measured or observed values of multiple variables, such as a patient's age, weight, metabolite level, and gene expression levels. A unique interpretation function specific to the IVDMIA would then combine and analyze these variables to yield a score. The intended use of the IVDMIA, for example, would be to diagnose disease or predict risk of disease based upon this score.

Examples of these "devices" are: gene expression profiling assay for breast cancer prognosis; and a device that integrates quantitative results from multiple immunoassays to obtain a qualitative "score” that predicts a person's risk of developing a disease or condition.

Early in 2008, several industry representatives and pharmacogenomics advocates strongly criticized the IVDMIA guidance, calling it untenable, and potentially illegal. Presenters at that FDA meeting claimed that the document failed to clearly define what the FDA considers IVDMIAs; does not explain how the agency's regulations would merge with CLIA's guidelines; and would lower incentive to innovation in personalized medicine.

While Genentech argues for greater FDA oversight of LDTs, the Washington Legal Foundation (Washington DC, USA) filed a citizen petition in 2006 requesting that FDA does not regulate LDTs as medical devices. The FDA has not yet responded to that petition.

Related Links:
US Food and Drug Administration
Genetech
The Centers for Medicare & Medicaid Services
Washington Legal Foundation


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.